Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COATS: CYP2C19-guided clopidogrel therapy in (D)OAC-treated PCI patients
2022-001093-55Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of clopidogrel in coronary arteriosclerosis, Atrial fibrillation (AFib) and venous thromboembolism (VTE), sponsored by Erasmus MC. Primary endpoint: Major and CRNM bleeding at 12 months. Started Apr 2022; status: active.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosisAtrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2022-001093-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001093-55.